

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



AIM Vaccine Co., Ltd.
艾美疫苗股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 06660)

VOLUNTARY ANNOUNCEMENT
COMPLETION OF SUBMISSION OF SUPPLEMENTARY DATA
FOR MARKET REGISTRATION OF
SERUM-FREE ITERATIVE RABIES VACCINE
REGISTRATION APPLICATION ACHIEVES IMPORTANT PROGRESS

This announcement is made by AIM Vaccine Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company of the latest business developments of the Group.

The Group’s wholly-owned subsidiary, AIM Rongyu (Ningbo) Biopharmaceutical Co., Ltd. (hereinafter referred to as “**AIM Rongyu**”), has previously submitted a market registration application to the National Medical Products Administration (“**NMPA**”) for its self-developed serum-free iterative rabies vaccine (Acceptance No.: CXSS2500044), and has successfully completed on-site inspection. In the first half of 2026, AIM Rongyu received a notice requesting supplementary data from the Center for Drug Evaluation of NMPA, which is a routine procedure in the vaccine review process. The Company has compiled and submitted the supplementary data to the Center for Drug Evaluation of NMPA in accordance with the review opinions, marking important progress in the registration application of the serum-free iterative rabies vaccine.

According to the results of the Phase III clinical trial that has completed unblinding, the Group’s serum-free iterative rabies vaccine has demonstrated favorable safety, immunogenicity and immunological persistence, and has fully met the pre-specified evaluation criteria of the clinical trial. AIM Rongyu has previously obtained the relevant production license for the serum-free iterative rabies vaccine. Upon the launch of this product, the Group will further consolidate its global leading position in the rabies vaccine field.

Rabies is the disease with the highest fatality rate in the world, with a fatality rate of nearly 100% after symptom onset. Currently, there is a lack of effective treatment for rabies in clinical practice; therefore, post-exposure prophylaxis is of critical importance, with the main preventive measure being vaccination with human rabies vaccine. There are currently two main types of rabies vaccines: serum-containing rabies vaccines and serum-free rabies vaccines. The mainstream Vero cell rabies vaccines and human diploid rabies vaccines currently available on the market both adopt serum-containing culture systems. Animal serum residues are a core cause of allergic reactions and local adverse reactions in vaccinated populations. The serum-free iterative rabies vaccine developed by the Group represents an innovation in cell culture technology, with no animal serum components added throughout the entire production process, fundamentally reducing the incidence of adverse reactions from the source and significantly improving safety.

China is the world's largest rabies vaccine market. According to statistics from China Insights Consultancy, driven by product updating and iteration and increased accessibility to rabies vaccines, the market size is projected to reach RMB14.8 billion by 2030. In accordance with the "Guidelines for the Prevention and Treatment of Rabies Exposure (2023 Edition)" (《狂犬病暴露預防處置工作規範(2023年版)》) issued by the National Disease Control and Prevention Administration and the National Health Commission, rabies vaccination clinics are required to be equipped with at least two different types of rabies vaccines. Leveraging its iterative technological advantages, the Group's product is expected to become the first choice for vaccination institutions.

As the world's second largest supplier of rabies vaccines, the Group is committed to leading the in-depth technology iteration and upgrading of rabies vaccines globally. It has completed the construction of a serum-free iterative rabies vaccine workshop that meets international standards, as well as the commercial-scale validation production, and is now capable of producing this product on a large scale. Once the product is approved, it can be rapidly launched into the market. Upon regulatory approval and commercialisation, this vaccine is expected to deliver a significant boost to the Group's results.

By order of the Board
AIM Vaccine Co., Ltd.
Chairman of the Board and CEO
Mr. Yan ZHOU

Beijing, the PRC, August 3, 2026

As at the date of this announcement, the Board comprises Mr. Yan ZHOU, Mr. Xin ZHOU, Mr. Shaojun JIA, Mr. Wen GUAN, Mr. Jie ZHOU and Ms. Ling LIU as executive directors; Mr. Jichen ZHAO as a non-executive director; and Professor Ker Wei PEI, Mr. Xiaoguang GUO, Mr. Hui OUYANG and Mr. Weicai SHAO as independent non-executive directors.